Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Research from X.L. Ou and co-researchers yields new findings on cancer vaccines
June 17th, 2008
" Dendritic cell (DC)-based cancer vaccines are currently being evaluated as novel anti-tumor vaccination strategies, but in some cases, they are demonstrated to have poor clinical efficacies than anticipated. A potential reason is immune tolerance due to the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO)," researchers in Guangzhou, People's Republic of China report. "The aim of this study was to determine whether blocking the activity of IDO might improve the anti-tumor efficacy of DC/Lewis lung carcinoma (LLC) fusion vaccine applied to the mouse LLC model. To prepare the DC/LLC fusion vaccine, DCs were fused with LLC using polyethylene glycol...
Source: Cancer Weekly (2008-06-17)
|
